A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results.

Background

Approximately 70% of patients with metastatic breast cancer (MBC) develop bone metastases. Despite advances in systemic treatment options and the use of bone targeted agents in the management of bone metastases to reduce skeletal morbidity, there remains an unmet need for further treatment options. Radium-223 (Ra

Methods

CARBON is a multi-centre, open-label phase IB/IIA study evaluating the combination of Ra

Results

In addition to bone metastases, 10/23 [44%] and 13/23 [57%] capecitabine + Ra

Conclusion

Capecitabine + Ra

Informations de copyright

© 2022 Published by Elsevier GmbH.

Déclaration de conflit d'intérêts

Janet Brown declared research grants (to her institution) from Amgen, AstraZeneca and Bayer and personal fees from Amgen, Novartis, BMS, Ipsen, Sandoz, MSD and Bayer and support for attending meetings from Ipsen.  Matthew Winter declared consulting fees from Gilead, Novartis and Eli Lilly, payment for lectures/presentations/speakers bureaus from Eli Lilly, Pfizer, Novartis and Easai and support for attending meetings and/or travel from Eli Lilly, Gilead, Novartis and Easai. Robert Coleman declared consulting fees from AstraZeneca,  Boehringer Ingelheim, ITM and Sanofi; speaker fees from Amgen, ITM, Novartis and Pierre Fabre; and has a patent pending and share options with Inbiomotion.  Caroline Wilson declared consultancy fees from Pfizer, Novartis, Amgen and Roche Iain MacPherson declared consultancy fees from AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Gilead, In3Bio, MSD, Novartis, Pfizer and Roche and travel support from Eisai and Roche. Richard Eastell declared consultancy funding from IDS, Sandoz, Samsung, Haoma Medica, CL Bio, Biocon, Takeda, meeting presentations from Pharmacosmos, Alexion and Amgen and grant funding from Amgen, Roche, Pharmacosmos and Alexion. Chris Twelves declared fees from AstraZenenca, Pfizer, Novartis, MSD and Eisai.  Sacha Howell declared speaker fees and advisory board fees from Pfizer. Carlo Palmieri declared grant funding from Daiichi Sankyo, Pfizer and Seagen, travel support from Gilead and Roche and honoraria from Astrazeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, Novartis, Pfizer and Roche. All other authors declared no conflicts of interests.